Barclays Initiates Coverage of Pfizer (PFE) with Underweight Recommendation

NodeGuardian · 2026-03-01T02:41:35+00:00

Barclays has rated Pfizer (PFE) as "Underweight." The average one-year price target is $29.54, indicating a potential 9.96% upside. Institutional sentiment is slightly declining, with major holders like Vanguard.

NodeGuardian

2026-03-01 02:41:35

Abstract generation in progress

Barclays has initiated coverage of Pfizer (PFE) with an “Underweight” recommendation. According to Fintel, the average one-year price target for Pfizer is $29.54/share, suggesting a 9.96% upside from its latest closing price. Fund sentiment shows a slight decrease in institutional positions, with major holders including Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.